×

Cellerant Appoints Rodney Young as Chief Financial Officer

SAN CARLOS, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic (blood forming) stem cell-based cellular and antibody therapies for blood disorders and cancer, announced that Rodney Young has joined the Company as Chief Financial Officer. Mr. Young brings more than 25 years of financial and executive experience in the life sciences field as a chief financial officer and investment banker.

"We are delighted to welcome Rodney to the Cellerant team. His vast financial, strategic and industry expertise will be critical as we progress our clinical programs and our pipeline of immuno-oncology therapeutic candidates," said Ram Mandalam, Ph.D., President and Chief Executive Officer of Cellerant Therapeutics.

"This is an exciting time at Cellerant," said Mr. Young. "The Company's CLT-008 cell therapy product has the potential to change the treatment paradigm for AML, and I look forward to helping the Company grow and advance its truly novel immunotherapy programs."

Mr. Young comes to Cellerant with significant corporate finance and leadership experience. Mr. Young was previously Chief Financial Officer at StemCells, Inc., a NASDAQ listed, public biotechnology company developing stem cell therapeutics for central nervous system disorders, where he had been responsible for raising over $200 million in financings. Most recently, he served as Chief Financial Officer at Allergen Research Corporation, where he had led the efforts in raising an $80 million private financing round. Earlier in his career, he was an investment banker at Lehman Brothers and SG Cowen, leading financing and merger and acquisition transactions focused in the healthcare, biotechnology, and pharmaceutical sectors. Mr. Young received his BA and MBA from the University of Chicago.

About Cellerant Therapeutics

Cellerant Therapeutics is a clinical stage biotechnology company focused on developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's programs include: CLT-008, an off-the-shelf cellular immunotherapy, under evaluation in a multicenter, open-label, randomized, controlled Phase 2 clinical trial in patients with de novo AML; CSC030-ADC, a preclinical monoclonal antibody drug conjugate that selectively targets and kills leukemic stem and blast cells responsible for initiating and maintaining disease; and CSC012, a preclinical monoclonal antibody targeting leukemic and pre-leukemic stem cells for acute leukemias and myelodysplastic syndromes. The Company is also developing next generation CAR product candidates leveraging its proprietary immunocellular therapy and antibody discovery and development platform.

For more information, visit: http://www.cellerant.com.

CONTACT: Cellerant Therapeutics, Inc. Jun Yoon Vice President, Corporate Development (650) 232-2122 info@cellerant.com Investor contact: Andrew McDonald Ph.D. LifeSci Advisors LLC (646) 597-6987 andrew@lifesciadvisors.comSource: Cellerant Therapeutics